Study guide
1.1 Patient Assessment, History, and Vital Signs
ARRT Radiation Therapy Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Patient Care & Education
1.1 Patient Assessment, History, and Vital Signs 1.2 Psychosocial Support & Coping Mechanisms 1.3 Patient & Family Education on Radiation Therapy 1.4 Radiation Side Effect Management: Skin & Mucosal Reactions 1.5 Radiation Side Effect Management: Systemic & Organ-Specific Side Effects 1.6 Nutritional Support & Management of Dysphagia/Odynophagia 1.7 Medical Emergencies in Radiation Oncology 1.8 Patient Rights, Informed Consent, and Advanced Directives 1.9 Ethical, Legal, and HIPAA Considerations for Radiation Therapists 1.10 Infection Control & Sterile Technique in Radiation Therapy 1.11 Transfer & Positioning Safety for Oncology Patients 1.12 Pharmacology & Contrast Media in Radiation Therapy 1.13 Cancer Epidemiology, Screening & Diagnostic Evaluation
2 Chapter 2: Radiation Physics, Radiobiology & Protection
2.1 Structure of Matter, Electromagnetic & Particulate Radiation 2.2 Radiation Production in Linear Accelerators & X-Ray Tubes 2.3 Photon & Electron Beam Interactions with Matter 2.4 Radiation Measurement Quantities, Units & Dosimeters 2.5 Radiation Protection Principles: ALARA, Time, Distance & Shielding 2.6 NCRP Dose Limits for Occupational & Public Exposure 2.7 Vault Design, Primary & Secondary Protective Barriers 2.8 Radiobiology Principles: Cell Survival Curves & Radiosensitivity (4 R's) 2.9 Linear Energy Transfer (LET) & Relative Biological Effectiveness (RBE) 2.10 Acute & Late Radiation Effects on Normal Tissues 2.11 Radiation Safety Rules, Emergency Procedures & Sealed Source Safety 2.12 MRI Magnetic Field Screening for Radiation Therapy Patients
3 Chapter 5: Treatment Sites, Tumors & Classification
5.1 Brain, Spinal Cord Tumors & Metastatic Patterns 5.2 Head & Neck Sites: Anatomy, Lymphatics & Patterns of Spread 5.3 Breast Cancer: Anatomy, Lymphatic Drainage & Radiation Considerations 5.4 Lung & Thoracic Tumors: Anatomy, Spread & Critical Structures 5.5 Abdomen, Pelvis, GI & GU Sites: Anatomy & Metastatic Patterns 5.6 Reproductive System Tumors: Prostate, Cervix & Related Sites 5.7 Lymphoma, Sarcoma, Skin, Leukemia & Oncologic Emergencies 5.8 Tumor Classification: Histopathology, Grade & Staging Systems
4 Chapter 3: Treatment Planning & Dosimetry
3.1 CT Simulation, Patient Positioning & Target Localization 3.2 Immobilization Devices & Radiopaque Marking Protocols 3.3 ICRU Target Volume Definitions (GTV, CTV, PTV, PRV, OAR) 3.4 Beam Modifiers: Wedges, Compensators, Bolus & MLC Systems 3.5 Depth Dose Characteristics: PDD, TMR, TPR & TAR Relationships 3.6 Monitor Unit (MU) Calculations & Clinical Dosimetry Formulas 3.7 3D Conformal Radiation Therapy (3D-CRT) Beam Arrangements 3.8 IMRT, VMAT & Inverse Planning Optimization Concepts 3.9 SRS, SBRT & Stereotactic Radiosurgery Techniques 3.10 Brachytherapy Principles, HDR, LDR & Isotopes 3.11 Dose Volume Histograms (DVH) & QUANTEC Tissue Tolerances
5 Chapter 4: Treatment Delivery, Image Guidance & QA
4.1 Pre-Treatment Chart Check & Plan Verification Protocols 4.2 Daily Patient Positioning, Setup Tolerances & Alignment Verification 4.3 Image-Guided Radiation Therapy (IGRT): Portal Imaging & CBCT Verification 4.4 Linear Accelerator Safety Systems, Interlocks & Gantry Controls 4.5 Special Techniques: TBI, TSI, SGRT & Gated Radiotherapy 4.6 Daily Linac Quality Assurance per AAPM TG-142 Specifications 4.7 Monthly & Annual Linac QA Requirements & Dosimetric Calibration 4.8 Patient-Specific IMRT QA & In-Vivo Dosimetry Verification 4.9 Machine Malfunctions, Override Protocols & Emergency Off Procedures 4.10 Record and Verify (R&V) Systems, EHR Integration & Treatment Documentation
1.1 Patient Assessment, History, and Vital Signs
Key Takeaways Explain This Topic AI
ECOG performance status ranges from 0 (fully active) to 5 (dead), where ECOG 2 indicates a patient ambulatory >50% of waking hours but unable to work.
Karnofsky Performance Scale (KPS) runs from 100 to 0, where KPS <70 indicates a patient unable to care for self and requiring institutional or equivalent care.
Neutropenic fever is defined as a single oral temperature ≥38.3°C (101.0°F) or ≥38.0°C (100.4°F) sustained over 1 hour, representing a medical emergency when Absolute Neutrophil Count (ANC) is <500/µL.
Hemoglobin levels <10 g/dL reduce tissue oxygenation and decrease the Oxygen Enhancement Ratio (OER), significantly impairing radiation-induced tumor cell kill.
Unintentional weight loss exceeding 5% in 30 days or 10% in 180 days indicates severe nutritional depletion requiring immediate clinical intervention and potential adaptive re-simulation.
Last updated: July 2026
1.1 Patient Assessment, History, and Vital Signs
Comprehensive patient assessment is the cornerstone of safe, effective radiation oncology care. Radiation therapists must perform continuous, systematic evaluations before, during, and after each course of radiotherapy. Because radiation therapy is delivered over multiple weeks, baseline assessments provide the benchmark against which acute toxicities, disease progression, and treatment responses are measured.
Oncology Health History
A detailed oncology health history establishes the patient's baseline clinical status and helps identify potential risks or contraindications during radiation delivery. The health history encompasses several core components:
Chief Complaint (CC): The primary symptom or diagnosis bringing the patient to radiation oncology.
History of Present Illness (HPI): Chronological account of tumor presentation, diagnostic biopsy results, pathological staging (TNM classification), histology, molecular markers, and anatomical localization.
Past Medical & Surgical History (PMH/PSH): Co-morbidities such as diabetes, cardiovascular disease, collagen vascular diseases (e.g., systemic lupus erythematosus, scleroderma—which significantly increase normal tissue radiosensitivity), and previous surgical resections.
Prior Oncology Interventions: Details of previous chemotherapy regimens (especially radiosensitizing agents like cisplatin or cardiotoxic agents like doxorubicin), immunotherapy, and prior external beam or brachytherapy courses (including exact field boundaries and accumulated doses to avoid normal tissue overdose).
Allergies & Current Medications: Documentation of known drug allergies, contrast medium hypersensitivity, anticoagulants (increasing bleeding risk during invasive procedures), and systemic corticosteroids.
Performance Status Scoring Systems
Performance status scales quantify a cancer patient's daily functional abilities and general well-being. They guide clinical decision-making regarding treatment tolerance, dose fractionation, and palliative versus curative intent.
ECOG Performance Status Scale
The Eastern Cooperative Oncology Group (ECOG) scale grades functional impairment from 0 to 5:
ECOG Grade Functional Ability & Clinical Description
0 Fully Active: Able to carry on all pre-disease performance without restriction.
1 Restricted Strenuous Activity: Light work allowed; ambulatory and able to carry out light house/office work.
2 Ambulatory (>50% Waking Hours): Capable of all self-care but unable to carry out work activities; up and about >50% of waking hours.
3 Limited Self-Care (<50% Waking Hours): Capable of only limited self-care; confined to bed or chair >50% of waking hours.
4 Completely Disabled: Cannot carry on any self-care; totally confined to bed or chair.
5 Deceased: Patient death.
Karnofsky Performance Scale (KPS)
The Karnofsky Performance Scale (KPS) uses an 11-point scale from 100 to 0 in 10-unit decrements:
100: Normal; no complaints; no evidence of disease.
90: Able to carry on normal activity; minor signs or symptoms of disease.
80: Normal activity with effort; some signs or symptoms of disease.
70: Cares for self; unable to carry on normal activity or do active work.
60: Requires occasional assistance, but is able to care for most of personal needs.
50: Requires considerable assistance and frequent medical care.
40: Disabled; requires special care and assistance.
30: Severely disabled; hospital admission indicated although death not imminent.
20: Very sick; hospital admission necessary; active supportive treatment necessary.
10: Moribund; fatal processes progressing rapidly.
- 0: Dead. +------------------------------------------------------------------+
- | PERFORMANCE STATUS COMPARISON |
- +------------------------------------+-----------------------------+
- | ECOG Grade | KPS Rating |
- +------------------------------------+-----------------------------+
- | 0 (Fully Active) | 90 - 100% |
- | 1 (Restricted Strenuous Work) | 70 - 80% |
- | 2 (Ambulatory >50% Waking) | 50 - 60% |
- | 3 (Bedbound >50% Waking) | 30 - 40% |
- | 4 (Completely Bedbound) | 10 - 20% |
- | 5 (Deceased) | 0% |
- +------------------------------------+-----------------------------+
- Vital Signs Assessment & Monitoring Thresholds
Baseline vital signs must be recorded prior to simulation and daily treatment when clinically indicated. Deviations from normal parameters dictate immediate intervention.
Body Temperature
Normal Range: 36.5°C to 37.5°C (97.7°F to 99.5°F).
Febrile Threshold: Single oral measurement ≥38.3°C (101.0°F) or ≥38.0°C (100.4°F) sustained over 1 hour.
Clinical Significance: In immunocompromised or neutropenic oncology patients, fever may be the sole presenting sign of life-threatening sepsis. Treatment must be paused and blood cultures ordered immediately.
Pulse & Heart Rate
Normal Range: 60 to 100 beats per minute (bpm).
Tachycardia (>100 bpm): Associated with pain, anxiety, anemia, fever, dehydration, or cardiac toxicity.
Bradycardia (<60 bpm): May indicate vagal stimulation, intrinsic cardiac conduction defects, or medication effects (e.g., beta-blockers).
Respiration
Normal Range: 12 to 20 breaths per minute.
Tachypnea (>20 breaths/min): Sign of respiratory distress, acute radiation pneumonitis, pulmonary embolism, pleural effusion, or severe anxiety.
Blood Pressure (BP)
Normal: Systolic <120 mmHg AND Diastolic <80 mmHg.
Hypertension Stage 1: Systolic 130–139 mmHg OR Diastolic 80–89 mmHg.
Hypertension Stage 2: Systolic ≥140 mmHg OR Diastolic ≥90 mmHg.
Hypotension: Systolic <90 mmHg OR Diastolic <60 mmHg. Orthostatic hypotension (drop in SBP >20 mmHg upon standing) increases fall risk during transfer from the treatment couch.
Pulse Oximetry ( S p O 2 SpO_2 Sp O 2 )
Normal: 95% to 100% on room air.
Hypoxemia ( S p O 2 < 90 % SpO_2 <90\% Sp O 2 < 90% ): Requires emergency supplemental oxygen administration and pulmonary assessment.
Baseline Diagnostic Laboratory Values
Radiation therapists must review complete blood count (CBC) values, particularly when large bone marrow reserves (pelvis, spine, sternum) are within the treatment field or during concurrent chemoradiotherapy.
Laboratory Parameter Normal Adult Reference Range Critical Threshold & Clinical Action
White Blood Cells (WBC) 4,500 – 11,000 /µL <2,000 /µL: Severe leukopenia; implement protective isolation.
Absolute Neutrophil Count (ANC) 1,500 – 8,000 /µL <500 /µL: Severe neutropenia; high risk of fatal infection. Hold treatment if febrile.
Hemoglobin (Hgb) Male: 13.8–17.2 g/dL; Female: 12.1–15.1 g/dL <10 g/dL: Tissue hypoxia reduces OER; consider transfusion. <8 g/dL: Hold treatment.
Platelets (PLT) 150,000 – 450,000 /µL <50,000 /µL: Thrombocytopenia; bleeding risk. <20,000 /µL: Spontaneous hemorrhage risk. [ OXYGEN ENHANCEMENT RATIO (OER) ]
- |
- +----------------------------+----------------------------+
- | |
- Well-Oxygenated Tissue (Hgb ≥10) Hypoxic Tissue (Hgb <10)
- | |
- Free radicals fixed by O2 Free radicals repaired
- | |
- High DNA double-strand breaks Increased radioresistance
- (Maximum cell kill achieved) (Treatment failure risk)
- Physical & Pain Assessment Protocols
Systematic physical assessment includes evaluating skin integrity, mucosal breakdown, weight change, and pain. Pain must be assessed using the standardized PQRST framework :
P (Provocation/Palliation): What aggravates or relieves the pain?
Q (Quality): Is the pain sharp, dull, burning, throbbing, or neuropathic?
R (Region/Radiation): Where is the pain located, and does it radiate?
S (Severity): 0 to 10 numerical rating scale (0 = no pain, 10 = worst imaginable pain).
T (Timing): Is the pain continuous, intermittent, or related to swallowing/movement?
Unintentional weight loss tracking is paramount. Weight loss >5% in 30 days alters body contours, rendering immobilization devices ill-fitting and causing geometric setup errors that compromise target coverage and organ-at-risk sparing.